Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Derma Sciences has acquired global exclusive licensing contract from the University of Southern California for an angiotensin analog, a topical application for the treatment of wounds such as diabetic ulcers, pressure ulcers, and burns, as well as for the reduction of scars resulting from surgical procedures.
Subscribe to our email newsletter
Derma Sciences acquired the technology license for an $840,000 up front payment, with certain milestone payments to University of Southern California (USC) based on regulatory and sales milestones, and royalties based on annual sales. The license includes a commitment on the part of Derma Sciences to develop the product, contributing an estimated $4-$5 million through Phase II. This will be defrayed in part by a continuation in National Institutes of Health (NIH) funding.
DSC127 has shown strong efficacy in NIH funded pre-clinical animal models in both accelerated healing of excisional injuries in diabetic animals as well as reduction of scars. The Phase II safety and efficacy clinical program is expected to begin in the first half of 2008 and be completed by the second half of 2009.
Laura Bolton, chief scientific advisor, Derma Sciences, said: “The biological effects of DSC127 seem well researched and sound. If the clinical studies match the pre-clinical results, the products from this technology have major potential in soft tissue and bone healing, dermatologic, surgical and oncologic applications. This molecule has passed rigorous testing with more promise than I have seen for any other active wound healing agent.”